ClinicalTrials.gg
CompletedNCT02690025glepaglutideUpdated Jun 21, 2017

A Phase 2 Trial Testing ZP1848 in Patients With SBS

A Phase 2 interventional study of ZP1848 in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 1 site in Denmark. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-06-21.

Sponsored by Zealand Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Short Bowel Syndrome with a site in Denmark — 4 open to participants now, 5 under way, 3 of them phase 3. Short Bowel Syndrome · Denmark.

Enrollment
13th of 21
18 · median 65
Started
2016
the only one that year
Phase 2
2 of 22
1 open now
Registered
7th of 22
by date
Lead sponsor
6 of 22
Zealand Pharma

Among the 22 studies in Short Bowel Syndrome with a site in Denmark, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2, and was the 7th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

4 of the 22 studies in Short Bowel Syndrome with a site in Denmark are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Short Bowel Syndrome with a site in Denmark, or all of them as a file.
02

Study summary

A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Following receipt of verbal and written information about the trial, the patient must provide signed before any trial related activity is carried out.
  • Age ≥ 18 years and ≤ 90 years
  • Stable SBS patients with intestinal insufficiency or failure, where the last surgical resection of gut tissue was performed at least 1 year ago
  • A stable PS volume ( \< 25% change in volume or energy content) for four weeks prior to randomization for patients requiring PS
  • Wet weight of fecal excretion ≥ 1500 g/day demonstrated during a hospital stay prior to screening or during at least one day of the first baseline balance study.
  • Stable body weight (\<5% weight deviance in the three months prior to screening)

Exclusion criteria

Exclusion Criteria:

  • Patients with known or suspected intestinal strictures of clinical relevance as judged by the Investigator
  • Active inflammatory bowel disease (IBD) or fistula during the screening period as judged by conventional means of the Investigator.
  • Crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization
  • Cardiac disease defined as: Decompensated heart failure ( class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening
  • History of cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) unless it can be documented that the patient has been in a disease-free state for at least 5 years (except colon cancer: patients with a history of colon cancer generally have to be excluded)
  • (by the MDRD formula) \<30 mL/min/1.73 m2
  • renal disease as judged by the Investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    ZP1848 High dose

    s.c. administration of high dose

    Drug: ZP1848

  • Experimental
    ZP1848 Medium dose

    s.c. administration of medium dose

    Drug: ZP1848

  • Experimental
    ZP1848 Low dose

    s.c. administration of low dose

    Drug: ZP1848

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary endpoint is the absolute change from baseline to the end of three week treatment periods of wet weight of ostomy output or diarrhea measured separately over each of the two treatment periods.

    Time frame: 3 weeks

Secondary outcomes

  1. Relative change from baseline to the end of treatment of wet weight of ostomy output or diarrhea measured separately over each of the two treatment periods

    Time frame: 3 weeks

  2. Absolute change from baseline to the end of treatment of urine weight measured separately over each of the two treatment periods

    Time frame: 3 weeks

  3. Relative change from baseline to the end of treatment of urine weight measured separately over each of the two treatment periods

    Time frame: 3 weeks

  4. Absolute change from baseline to the end of treatment of wet weight absorption measured separately over each of the two treatment periods

    Time frame: 3 weeks

  5. Relative change from baseline to the end of treatment of wet weight absorption measured separately over each of the two treatment periods

    Time frame: 3 weeks

  6. Absolute change from baseline to the end of treatment of the intestinal absorption of electrolytes measured separately over each of the two treatment periods

    Time frame: 3 weeks

  7. Relative change from baseline to the end of treatment of the intestinal absorption of electrolytes measured separately over each of the two treatment periods

    Time frame: 3 weeks

  8. Absolute change from baseline to the end of treatment of the intestinal absorption of macronutrients measured separately over each of the two treatment periods

    Time frame: 3 weeks

  9. Relative change from baseline to the end of treatment of the intestinal absorption of macronutrients measured separately over each of the two treatment periods

    Time frame: 3 weeks

  10. Change in SF-36 score

    Time frame: 3 weeks

  11. Incidence of Adverse Events

    Time frame: 15 weeks

  12. Incidence of Anti Drug Antibodies

    Time frame: 15 weeks

  13. Absolute change from baseline to the end of treatment of urine weight minus oral intake measured separately over each of the two treatment periods

    Time frame: 3 weeks

  14. Relative change from baseline to the end of treatment of urine weight minus oral intake measured separately over each of the two treatment periods

    Time frame: 3 weeks

07

Study locations

1 site
  • Rigshospitalet
    Copenhagen, Denmark
08

References and documents

Publications

  • Hvistendahl MK, Naimi RM, Hansen SH, Rehfeld JF, Kissow H, Pedersen J, Dragsted LO, Sonne DP, Knop FK, Jeppesen PB. Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. JPEN J Parenter Enteral Nutr. 2022 May;46(4):923-935. doi: 10.1002/jpen.2224. Epub 2021 Sep 1. PubMed 34287979 ↗
  • Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Gronbaek H, Moller HJ, Vilstrup H, Steensberg A, Jeppesen PB. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine. 2019 Aug;46:444-451. doi: 10.1016/j.ebiom.2019.07.016. Epub 2019 Jul 17. PubMed 31326433 ↗
  • Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. doi: 10.1016/S2468-1253(19)30077-9. Epub 2019 Mar 15. PubMed 30880176 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Feb 24, 2016
Start
Feb 2016
Primary completionActual
May 2017
CompletionActual
May 2017
Last update
Jun 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02690025
Lead sponsor
Zealand Pharma
Collaborators
Larix A/S
Responsible party
Sponsor
First posted
Feb 24, 2016
Start date
Feb 2016
Primary completion
May 2017
Completion
May 2017
Last update
Jun 21, 2017

Study contacts

Gertrud Koefoed Rasmussen, MSc
study director · Zealand Pharma A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion